Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Study of Iberdomide (Cc220) Maintenance After Autologous Stem Cell Transplantation in Newly Diagnosed Multiple Myeloma Patients

NCT04564703 is registered in ClinicalTrials.gov with Stichting European Myeloma Network as lead sponsor.

NCT NCT04564703
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04564703 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Study of Iberdomide (Cc220) Maintenance After Autologous Stem Cell Transplantation in Newly Diagnosed Multiple Myeloma Patients
Lead sponsor
Stichting European Myeloma Network
Phase
Phase 2
Overall status
Active, not recruiting
Start date
February 22, 2021
Completion date
December 31, 2027
Enrollment
160 (estimated)
Sites
22

Conditions

As the registry lists them; a condition with its own page is linked.

multiple myeloma